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Ancillary Techniques on Direct-Smear Aspirate Slides
A Significant Evolution for Cytopathology Techniques
Stewart M. Knoepp, MD, PhD1 and Michael H. Roh, MD, PhD
Numerous cytologic techniques aimed at effectively acquiring patient material for molecular testing have been proposed.
Such techniques are becoming ever more important in an age of personalized medicine. In this commentary, the authors
explored some more commonly proposed techniques to aid in the molecular testing of cytologic specimens. These techni-
ques include the use of cell blocks, direct cytologic smears, filter paper storage, frozen samples, and enriched cellular
techniques such as ThinPrep and cytospin preparations. Direct-smeared slides demonstrate excellent preservation of
DNA, are easy to prepare, and are amenable to immediate adequacy at the time of the fine-needle aspiration (FNA) pro-
cedure as well as effective subsequent tumor purity estimation. Cell block methods cannot be assessed at the time of
FNA and often demonstrate insufficiency, whereas filter paper and frozen techniques do not allow for the direct assess-
ment of the presence and purity of tumor cells in the sample. Direct-smeared slides are emerging as the most effective
preparation and storage medium of cytologic material to be used for molecular testing. Their cost-effectiveness, ease of
use, and reliability have cemented them as the optimal solution for cytopathologists to fulfill the role of providing
advanced molecular testing on patient samples. Cancer (Cancer Cytopathol) 2013;121:120-28. VC 2012 American Cancer
Society.
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INTRODUCTION
With the increasing emphasis placed on personalized medicine in today’s modern health care systems,
pathologists are experiencing steady increases in the number of requests for molecular testing on patient
specimens. DNA-based mutational analyses are aimed at detecting molecular aberrations in tumors that
may portend response to targeted therapeutics. Not surprisingly, such testing becomes most relevant in
patients with high-stage, surgically unresectable malignant disease. In this context, smaller biopsies associ-
ated with minimal complications are desirable for the patient. Cytologic fine-needle aspirations (FNAs)
are especially useful in this regard because they represent a rapid, efficient, and minimally invasive means
with which to sample superficial and deep-seated lesions. Accordingly, cytopathologists are often called on
to serve as liaisons between clinicians, oncologists, and molecular pathologists by facilitating molecular
testing on FNA samples. Although molecular testing on FNA samples is not a novel notion, the increasing
variety and complexity of tests has created both challenges and opportunities for cytopathologists.1,2 Cyto-
pathologists are expected to implement the most optimal sample collection methods and workflow techni-
ques and serve as advisers to clinicians in selecting appropriate molecular tests.
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Commentary
The principal goal of this commentary is to discuss
the direct-smeared slide as an optimal platform for prepar-
ing small patient biopsies for subsequent molecular test-
ing. To facilitate this goal, it is first helpful to present the
following 3 objectives: 1) to make the case for FNA as the
optimal procedure for initial sample acquisition; 2) to
briefly consider select examples of current and future mo-
lecular techniques that may be routinely requested using
cytologic specimens; and 3) to discuss the advantages and
disadvantages of various other platforms (eg, cell blocks,
Whatman filter paper cards, frozen specimens, and cellu-
lar enrichment techniques) for performing molecular
tests.
Use of FNA to Aid in the Molecular
Analysis of Patient Samples
Although FNA and core needle biopsy (CNB) represent
complementary methods for obtaining tissue from both
palpable and nonpalpable lesions, the use of FNA to ac-
quire target DNA is advantageous over CNB in several
respects: 1) FNA can sample a wider area of the lesion; 2)
FNA allows for the acquisition of tumor cells with lower
contamination by stromal tissue; and, most importantly,
3) FNA allows for rapid on-site adequacy assessments and
the communication of preliminary diagnoses to the clini-
cal care providers.2 Cytopathologists who provide on-site
assistance during FNAs are therefore not only in a unique
position to triage freshly obtained material for ancillary
tests, but also to ensure that enough material has been
gathered for molecular analysis while the patient is still ac-
cessible. In addition to molecular polymerase chain reac-
tion (PCR)-based studies, other ancillary tests facilitated
by on-site assessments include immunocytochemistry
(ICC), conventional cytogenetics, fluorescence in situ
hybridization (FISH), flow cytometry, and microbiologic
culture.
Selected Existing and Emerging Molecular
Studies Applied to FNA Specimens
The repertoire of molecular tests applied to nongyneco-
logic cytology specimens is steadily growing.1,2 Salient
examples include PCR-based and FISH-based assays to
determine the presence of specific gene rearrangements in
patients with lymphoproliferative disorders and soft tissue
neoplasms, including small round blue cell tumors.3-9 In
addition, FISH-based assays have served as valuable
adjuncts in the diagnosis of urothelial cell carcinomas and
the determination of human epidermal growth factor re-
ceptor 2 (HER2)/neu gene amplification in patients with
breast cancer.10,11
Thyroid FNAs
Thyroid FNAs play a crucial role in the preoperative
assessment of thyroid nodules and the triaging of patients
for surgical management.12 Recently, the application of
ancillary molecular studies to thyroid FNAs has exploited
the currently understood molecular genetic aberrations
associated with thyroid follicular neoplasms.13 For exam-
ple, an activating mutation in BRAF resulting in the
V600E substitution is present in nearly one-half of papil-
lary thyroid carcinomas, and the RET-PTC and paired
box gene-8–peroxisome proliferator-activated receptor
gamma (PAX8-PPARc) translocations are found in
approximately 20% and 35%, respectively, of papillary
thyroid carcinomas and follicular carcinomas. Point
mutations in RAS proto-oncogenes are noted in a variety
of thyroid neoplasms, including papillary thyroid carci-
noma, follicular carcinoma, and follicular adenomas.
The application of molecular genetic assays to exam-
ine thyroid FNA material for the above mutations has
shown that the presence of any one of these mutations is
strongly indicative of malignancy on surgical follow-up.14
Molecular testing particularly improves the predictive
value of thyroid FNAs in which an indeterminate (ie,
atypia/follicular lesion of undetermined significance) di-
agnosis is rendered.15-17 Therefore, molecular testing can
serve an important role in these cases.
Non-Small Cell Lung Carcinoma FNAs
Specific chemotherapeutic agents for lung cancer are
available for the 2 most common subtypes of non-small
cell lung carcinoma (NSCLC): adenocarcinoma and squa-
mous cell carcinoma (SQC). A recent phase 3 study dem-
onstrated a significant improvement in overall survival in
patients with pulmonary adenocarcinoma who were
treated with the combination of cisplatin and pemetrexed
versus those treated with cisplatin and gemcitabine.18 In
contrast, the combination of cisplatin plus gemcitabine
was found to be superior to that of cisplatin and peme-
trexed for patients with SQC. FNAs of lung adenocarci-
noma are triaged, at increasing frequency, for further
molecular mutational analysis of the receptor tyrosine
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kinase, epidermal growth factor receptor (EGFR), and
KRAS, and rearrangements involving the gene encoding
the tyrosine kinase, anaplastic lymphoma kinase
(ALK).19,20 These mutations are mutually exclusive.
Patients with adenocarcinomas harboring EGFR muta-
tions are candidates for treatment with tyrosine kinase
inhibitors such as erlotinib and gefitinib. Recently, the ty-
rosine kinase inhibitor crizotinib has been approved as tar-
geted therapy for patients with lung adenocarcinomas
harboring ALK rearrangements.20 Hence, ensuring
adequate lesional material during FNAs for the specific
subclassification of NSCLC and subsequent molecular
testing is paramount.
Routine cytomorphology is often sufficient to dis-
tinguish between pulmonary adenocarcinoma and SQC.
Nonetheless, in a subset of cases, the distinction is difficult
and ICC can be useful for the subclassification of these
NSCLCs. Adenocarcinomas often express napsin A and
thyroid transcription factor-1 (TTF-1) and are usually
negative for cytokeratin (CK) 5/6 and p63.21 Conversely,
SQCs are typically negative for napsin A and TTF-1,
whereas they are virtually always immunoreactive for
CK5/6 and p63.
Melanoma FNAs
FNA represents a minimally invasive means with
which to establish a tissue diagnosis of metastatic mela-
noma, allowing for accurate staging and prompt clinical
management. ICC for S-100, HMB-45, and melan-A/
Melanoma Antigen Recognized by T cells (MART-1) can
be applied to challenging cases to confirm the diagnosis of
metastatic melanoma. Recently, investigators have found
that approximately 40% to 50% of melanomas harbor
activating mutations in BRAF; V600E and V600K repre-
sent the 2 most commonmutations.22-24 Because vemura-
fenib has recently been approved for the treatment of
patients with advanced stage melanomas harboring BRAF
mutations, there is increased attention to molecular diag-
nostic assays designed to detect these mutations in FNA
samples from patients with melanoma.
Platforms Used for the Performance of
Molecular Studies
Various techniques for sample collection for molecular
tests have been used, either as a routine part of the FNA
procedure or as a separately collected banked sample (Ta-
ble 1). Each has unique features that can be assessed for
suitability with subsequent molecular testing.
Cell Blocks
Cell blocks are traditionally used by many laborato-
ries for the performance of ancillary ICC and molecular
studies; they have notable advantages and weaknesses.
The advantages of cell blocks include: 1) formalin-fixed,
paraffin-embedded tissue is treated similarly to that of tra-
ditional surgical pathology blocks; 2) multiple serial sec-
tions for ancillary studies may be prepared; and 3) a
banked archive is maintained for future studies. The dis-
advantages of cell blocks include: 1) limited or no cellular-
ity in a subset of cases; 2) an inability to assess cellularity
and adequacy at the time of procedure; 3) the pooled
nature of the sample; and 4) the possibility that deeper
sections from the cell block may not contain the tumor
cells observed on the originally prepared hematoxylin and
eosin-stained slide. Of these, variability in cell block cellu-
larity (ie, sparse cellularity or acellularity in a subset of
cases) represents the most significant limitation. To exam-
ine this in our laboratory practice, we retrospectively ana-
lyzed the cellularity of cell blocks in 76 consecutive
endobronchial ultrasound-guided FNAs performed at our





















Direct smears Yes Yes Yes Yes, limited
Fresh frozen sample (microcentrifuge tube) No Yes No Yes
ThinPrep/cytospin Yes No Yes Yes, limited
Filter paper (eg, Whatman filter paper cards) No Yes No Yes
aDeeper sections of the cell block used for molecular testing are not visualized directly.
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institution that were diagnosed as being positive for
malignancy. We observed that 28 (37%) cell blocks were
acellular and an additional 15 (20%) cell blocks exhibited
sparse/borderline cellularity (Fig. 1). Dedicated passes to
enrich the cell block may help in some cases, but do not
completely alleviate this limitation (Fig. 1). Compound-
ing this issue, the ability to ensure adequate cellularity of
the cell block at the time of the FNA procedure is not pos-
sible because processing is not usually complete until the
following day. The third significant weakness of the cell
block is that it represents a pooled specimen from multi-
ple passes and therefore the tumor cell population from
high-yield needle passes may be diluted by background
benign elements in off-target needle passes. This is prob-
lematic because the analytic sensitivity of molecular diag-
nostic assays depends on a percentage tumor cellularity
threshold, below which false-negative results will occur
(ie, contaminating benign tissue will be negative for the
molecular abnormality being tested). For example, in our
molecular diagnostics laboratory, PCR-based assays
designed to detect BRAF and KRAS mutations require a
minimum percentage tumor cellularity of 10% and 30%,
respectively. In published studies from our laboratory, we
have noted 2 incidents in which a positive mutation result
was obtained from tumor-enriched areas on direct smears
whereas corresponding cell blocks in these 2 cases demon-
strated false-negative results.25,26
Filter Paper Storage or Fresh-Frozen
Samples (Microcentrifuge Tube)
One innovative approach to the storage of samples
for molecular studies involves aliquoting an amount of
aspirated FNAmaterial directly onto a small piece of filter
paper, which can then be stored at room temperature until
needed for molecular analysis. da Cunha Santos et al
applied molecular diagnostic studies to FNA material
from NSCLCs stored on Whatman filter paper cards, and
demonstrated that high-quality DNA could be extracted
from these cards after months of storage at room tempera-
ture.27 This method is advantageous because of the ease of
setup and the low cost of reagents and storage conditions.
However, a serious drawback still remains in that tumor
purity and sample adequacy in the filter paper cards can-
not be directly ascertained with certainty; there is a limited
ability to determine whether adequate amounts of tumor
cells were sequestered on the filter paper card because the
FIGURE 1. A retrospective analysis of cell block cellularity in fine-
needle aspiration (FNA) specimens is shown. Cell block sections
from 76 consecutive endobronchial ultrasound-guided FNA sam-
ples were stained with hematoxylin and eosin and examined and
assessed in terms of overall cellularity. Acellular cell blocks were
designated as exhibiting inadequate cellularity. Sparsely cellular
cell blocks (those having < 100 cells) were designated as exhibit-
ing borderline cellularity. Moderately cellular and abundantly cellu-
lar cell blocks exhibited between 100 to 300 cells and > 300 cells,
respectively. (A) Representative photomicrographs for each of
the 4 categories are shown (original magnification  40). (B) Of
the 76 cell blocks examined, 28 (37%), 15 (20%), 17 (22%), and 16
(21%) exhibited inadequate, borderline, moderate, and abundant
cellularity, respectively. Cell blocks exhibiting inadequate to bor-
derline cellularity would be anticipated to lead to potentially false-
negative results inmolecular assays,whereas cell blocks exhibiting
moderate to abundant cellularity would more likely lead to satis-
factory, informative results in molecular assays. (C) Of the 76 con-
secutive FNA specimens examined, on-site assessments of
adequacy were performed in 70 cases. In each of these 70 cases,
information regarding the number of dedicated passes for the cell
block was obtained; 0, 1, 2, or 3 dedicated passes were performed
in 47 cases, 10 cases, 10 cases, and 3 cases, respectively. The per-
centage of cases with cell blocks exhibiting inadequate to border-
line and moderate to abundant cellularity as a function of the
number of dedicated passes is shown in the bar graph. The actual
numbers of cases in each category are included in the bars.
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cells cannot be observed. To determine whether adequate
cells are present, one must examine a smear made from
the same pass and extrapolate. Even in cases in which
DNA is successfully extracted, it is not possible to deter-
mine with certainty the ratio of genetic material contrib-
uted by tumor cells and contaminating benign cellular
elements because of the inability to directly observe the
cells present on the filter paper cards.
Similar to the filter paper technique, an aliquot
from the FNA specimen may be placed in a small tube
containing cryopreservative and frozen for future use.
This method helps to guarantee long-term stability, espe-
cially for RNA, which is much more vulnerable to hydro-
lytic degradation than DNA.28 Depending on the
amount of cryopreserved material, an aliquot of the sam-
ple can be used, upon thawing, to prepare a Diff-Quik–
stained cytospin slide. Nonetheless, if this is not per-
formed and the frozen sample is directly submitted for
molecular testing in its entirety, the similar limitations
noted for the filter paper storage approach still apply (ie,
the sample cannot be directly observed to ensure the pres-
ence and purity of tumor cells).
Routine Cytology Slides: Air-Dried and Alcohol-
Fixed Direct Smears and Enriched Preparations
Routine cytology slides have the advantage that
DNA is readily extractable and reasonably stable (ie, at
least 6 months and up to and exceeding 5 years in some
cases).29 Enriched slides such as ThinPrep or cytospin
slides share some limitations with cell blocks: they are pre-
pared from homogenized, pooled liquid-based samples
derived frommultiple passes and they are not available for
the assessment of cellularity at the time of the procedure.
Direct smears prepared on-site are not associated with
these limitations. Freshly prepared, unstained direct
smears may either be air-dried or fixed in alcohol and
FIGURE 2. Traditional and alternative, modified approaches
to the triage of fine-needle aspiration (FNA) passes are
shown. An example of the traditional approach to a triage of
FNA passes is shown in the top panel. Here, each FNA pass
leads to the creation of 2 smears: 1 air-dried smear for Diff-
Quik (DQ) staining and 1 alcohol-fixed smear for Papanico-
laou (Pap) staining. The needle rinse is used for cell block
preparation. Dedicated passes for the needle rinse is a strat-
egy typically used to increase the likelihood that the pre-
pared cell block will exhibit adequate cellularity for ancillary
studies. An alternative, modified approach to the triage of
FNA passes is shown in the bottom panel. In this scenario,
the contents of a given FNA pass are distributed over multi-
ple smears including the routine air-dried, DQ-stained smear
and the alcohol-fixed, Pap-stained smear. Extra unstained
(Uns) smears can be used for immunocytochemistry or sub-
sequently stained for tumor cell microdissection and subse-
quent molecular analysis. Needle rinses including dedicated
passes are still used for cell block preparation.
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represent effective platforms for ICC and molecular stud-
ies.25,26,30-32 To observe tumor cells to ensure adequacy
for DNA extraction for molecular studies, it is easiest to
use stained slides. Although both alcohol-fixed Papanico-
laou-stained smears and air-dried Diff-Quik–stained
smears are suitable for DNA extraction, we prefer to use
Diff-Quik staining because DNA appears to be better pre-
served. Specifically, a recent study by Killian et al suggests
that Diff-Quik–stained smears can provide high-quality
DNA even if archived for a prolonged period, allowing
for the performance of sophisticated molecular diagnostic
studies such as high-resolution comparative genomic
hybridization assays.29 In this study, Killian et al observed
DNA degradation as a function of age for archived Papa-
nicolaou-stained smears.
Traditionally, during FNA procedures, each needle
pass leads to the preparation of 2 smears: 1 that is air-
dried for rapid Diff-Quik staining and another that is
alcohol-fixed and subsequently stained using the Papani-
colaou method (Fig. 2). However, depending on the
amount of material that is aspirated, it is usually possi-
ble to generate additional smears (in our experience, at
least 2 additional smears) per FNA pass (Fig. 2) (see
Supplemental Video). The presence of tumor cells on
the Diff-Quik–stained smear, determined during the
on-site assessment of adequacy, can be used as an indi-
cator of tumor cellularity on unstained direct smears
resulting from the same pass. Nonetheless, because this
represents an extrapolated approach, we prefer to assess
the presence of tumor cells on the unstained direct
smears by light microscopy. Specifically, the size and ar-
chitectural configuration of the tumor cells in the
unstained slides can be directly compared with the Diff-
Quik–stained slides and this can be facilitated by flip-
ping the condenser (Fig. 3). For slides destined for mo-
lecular studies, staining of an extra, unstained smear
with Diff-Quik is preferable because the tumor cells can
then be directly observed and selected for
FIGURE 3. Assessment of cellularity on unstained smears is
shown. In Figure 2, a modified approach to fine-needle aspi-
ration (FNA) triage was highlighted and the material expelled
from the needle was distributed over multiple smears, includ-
ing unstained smears and the routine Diff-Quik–stained and
Papanicolaou-stained smears. (Top) For a given pass, visual-
ization of tumor cells on the Diff-Quik–stained smear during
the on-site assessment would suggest the presence of tumor
cells in the unstained smears. In addition, unstained smears
can be assessed directly for cellularity under the light micro-
scope. (Middle) Although tumor cells adopting similar config-
urations as seen on the Diff-Quik–stained smear can be
difficult to observe while the condenser is in place, (Bottom)
flipping the condenser can facilitate tumor cell visualization.
The example depicted in this figure is of an FNA of a meta-
static melanoma.
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microdissection, DNA extraction, and molecular analy-
sis (Fig. 4). For the purposes of tumor microdissection
from smears, we routinely use the Pinpoint Slide DNA
Isolation System (Zymo Research, Irvine, Calif).
Regardless of the subsequent molecular test being per-
formed, the use of smears for molecular testing is ad-
vantageous because the cellularity of the smears can be
directly assessed at the time of the FNA. Areas of the
smear enriched with tumor cells can be directly
observed and microdissected, allowing for isolation of
DNA. We and others have previously reported that
EGFR and KRAS mutational analysis can be applied to
stained cytologic smears of NSCLCs.26,33-36 We have
also successfully applied this methodology to Diff-
Quik–stained smears of metastatic melanoma for BRAF
mutational testing.26 Overall, we observed that fresh,
noncoverslipped Diff-Quik–stained smears as well as
archived smears, decoverslipped in xylene, are suitable
for these purposes.25,26
Extra unstained, air-dried direct smears also provide
a robust source of material for ICC, which has been dem-
onstrated in our laboratory.25,30-32 In our practice, we
routinely use positively charged slides for preparing
smears; the use of positively charged slides for preparing
unstained smears is particularly beneficial for enhancing
cellular retention on the slides during processing for ICC.
Slides destined for ICC are first fixed in formalin for 30
minutes to 60 minutes followed by antigen retrieval and
immunostaining. Formalin fixation of smears approxi-
mates the formalin fixation conditions for the processing
of cell blocks, biopsies, and resection specimens. In this
regard, we use a combination of formalin-fixed, paraffin-
embedded tissue sections and/or unstained, formalin-
fixed direct smears for positive controls. In our experience,
unstained direct smears in high quantities can be prepared
using centrifuged cellular material from effusion speci-
mens and these can be used for positive control ICC reac-
tions.32 We acknowledge that the use of unstained smears
for ICC-positive controls is preferable within this context.
Negative control immunostains are performed on
unstained direct smears, for a given case, by omitting the
primary antibody during the ICC reaction.
In our laboratory, this methodology has been applied
to several clinical scenarios, such as the subclassification of
pulmonary adenocarcinoma and squamous cell carci-
noma30; the diagnosis of metastatic melanoma25; and the
confirmation of metastatic Merkel cell carcinomas,31 malig-
nant effusions,32 and Hodgkin lymphomas. Specifically, we
have successfully performed ICC for a finite number of anti-
bodies (including TTF-1, napsin A, p63, S-100, HMB-45,
MART-1, CK7, CK20, cluster of differentiation [CD] 56,
synaptophysin, epithelial membrane antigen, MOC-31,
CDX-2, PAX8, calretinin, CD15, and CD30) on unstained
direct smears using the Ventana Autostainer (VentanaMed-
ical Systems, Tucson, Ariz). Background staining can repre-
sent a problematic issue that is associated with ICC
performed on direct smears. Although we occasionally
observe unacceptably high background staining in relation
to the true signal, this is relatively uncommon. In our expe-
rience with the above markers, when mild background
staining is observed, the signal-to-background staining ratio
remains high.
Finally, cytologic smears are optimal for the per-
formance of FISH because whole nuclei of tumor cells are
being examined. Thus, direct smears can be used, in addi-
tion to cell blocks, for FISH studies.2
Conclusions
By considering that FNA is ideally suited for obtaining
patient samples for diagnostic and molecular testing, and
FIGURE 4. Microdissection of tumor cells from a Diff-Quik–
stained smear for DNA isolation using the Pinpoint Slide DNA
Isolation System (Zymo Research, Irvine, Calif) is shown. A
noncoverslipped Diff-Quik–stained smear or a previously cov-
erslipped Diff-Quik–stained smear that has been decover-
slipped in xylene can be examined to identify tumor-enriched
areas by light microscopy. The area of interest is then marked
on the underside of the smear. The Pinpoint solution is then
applied to the area of interest and allowed to dry. A sterile
scalpel subsequently is used to carefully microdissect the tu-
mor cells embedded in the Pinpoint solution and to transfer
the material to an Eppendorf tube (Eppendorf, Oldenburg,
Germany) for subsequent DNA extraction. The use of the Pin-
point solution minimizes the dispersal and aerosolization of
cellular material during microdissection.
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reviewing some of the more common tests as well as other
sample collection methods, it is easy to appreciate the use-
fulness of routine FNA smears in providing optimal mate-
rial for the storage and harvesting of the cellular material
needed for such testing. Air-dried, Diff-Quik–stained
smears for use in PCR-based tests are easy to prepare,
require minimal processing and storage complexity, and
are less cumbersome to microdissect than cell blocks.
DNA extracted from direct smears is highly reliable and
provides satisfactory molecular test results. Because smears
can be directly observed at the time of the FNA procedure,
the pathologist can ensure that adequate material has been
obtained for cytodiagnosis and necessary ancillary tests.
Routine cytologic smears, when incorporated into the tri-
age and workflow for performing ancillary molecular
tests, represent a cost-effective and powerful tool to aid in
effective molecular testing in the age of personalized
medicine.
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